MichaelPDonahoeMD

Pulmonology • Pittsburgh, PA

Critical Care Medicine, Pleural Disease

Professor of Medicine, University Pittsburgh School of Medicine Executive Vice Chair, Department of Medicine

Join to view full profile

Dr. Donahoe is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Donahoe's full profile

Already have an account?

Office
3601 5th Ave
Fl 4
Pittsburgh, PA 15213
Phone+1 412-648-6161

Fax+1 412-648-6869

Summary

Dr. Michael Donahoe is a pulmonologist in Pittsburgh, PA and is affiliated with multiple hospitals in the area, including UPMC Presbyterian, UPMC Magee-Womens Hospital, UPMC East, and UPMC Presbyterian Shadyside - Shadyside. He received his medical degree from Drexel University College of Medicine and has been in practice 34 years.

Education & Training

UPMC Medical EducationFellowship, Pulmonary Disease and Critical Care Medicine, 1987 - 1989
UPMC Medical EducationFellowship, Pulmonary Disease and Critical Care Medicine, 1986 - 1987
UPMC Medical EducationResidency, Internal Medicine, 1983 - 1986
Drexel University College of MedicineClass of 1983

Certifications & Licensure

PA State Medical License 1984 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Critical Care Medicine
American Board of Internal Medicine Pulmonary Disease

Awards, Honors, & Recognition

Top MD Consumers Checkbook

Clinical Trials

Acute Respiratory Distress Syndrome Clinical Network (ARDSNet) Start of enrollment: 1994 Sep 01
Completed
Phase 3
Aerosol Cyclosporine in Chronic Obstructive Pulmonary Disease (COPD) Start of enrollment: 2007 Oct 01
Completed
Phase 1
Oral Cyclosporine in Chronic Obstructive Pulmonary Disease Start of enrollment: 2009 Sep 01
Completed
Phase 1, Phase 2
Combined PEX, Rituximab and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations Start of enrollment: 2011 Mar 01
Completed
Phase 1, Phase 2
Human Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome (START) Start of enrollment: 2014 Mar 15
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

60 citations
Discovery of the gene signature for acute lung injury in patients with sepsis
Judie A. Howrylak, Tamas Dolinay, Lorrie Lucht, Zhaoxi Wang, David C. Christiani
Physiological Genomics. 2009-04-01
394 citations
Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial.
Michael A. Matthay, Carolyn S. Calfee, Hanjing Zhuo, B. Taylor Thompson, Jennifer G. Wilson
The Lancet. Respiratory Medicine. 2019-02-01
1064 citations
Intensity of renal support in critically ill patients with acute kidney injury
Paul M. Palevsky, Jane Hongyuan Zhang, Theresa Z. O'Connor, Glenn M. Chertow, Susan T. Crowley
The New England Journal of Medicine. 2008-07-03